Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mcbride malaysia sdn. bhd. - taurine; stichopus horrens extract -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

gnc livewell malaysia sdn. bhd. - taurine -

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - taurine (unii: 1eqv5mly3d) (taurine - unii:1eqv5mly3d) -

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - l-taurine 15x, 20x, 30x, 60x, 200x - for the temporary relief of muscle fatigue, cramping, or spasm, difficulty losing weight, anxiousness, sadness, restlessness, or sleep disturbance.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

United States - English - NLM (National Library of Medicine)

professional complementary health formulas - l-taurine 4x, 7x, 12x - for the temporary relief of muscle fatigue, cramping, or spasm, difficulty losing weight, anxiousness, sadness, restlessness, or sleep disturbance.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Australia - English - Department of Health (Therapeutic Goods Administration)

bio concepts pty ltd - taurine, quantity: 1000 mg - capsule, hard - excipient ingredients: silicon dioxide; hypromellose; purified water; acacia; sunflower oil; oryza sativa - maintain/support natural liver cleansing/detoxification processes ; maintain/support cardiovascular system health ; helps maintain/support healthy heart function ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support bile production ; maintain/support absorption of dietary (state vitamin/mineral/nutrient) ; maintain/support general mental wellbeing ; maintain/support brain function ; maintain/support brain health ; maintain/support nervous system health ; maintain/support nervous system function

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cta nutriceuticals (asia) sdn bhd - taurine -

Canada - English - Health Canada

novartis pharmaceuticals canada inc - midostaurin - capsule - 25mg - midostaurin 25mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - midostaurin, quantity: 25 mg - capsule, soft - excipient ingredients: corn oil peg-6 esters; gelatin; peg-40 hydrogenated castor oil; macrogol 400; titanium dioxide; glycerol; dl-alpha-tocopherol; purified water; iron oxide red; iron oxide yellow; ethanol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - rydapt is indicated:,? in combination with standard anthracycline and cytarabine induction and cytarabine consolidation chemotherapy, followed in patients in complete response by single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive ? for the treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated haematological neoplasms (sm-ahn), or mast cell leukaemia (mcl).

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - midostaurin (unii: id912s5von) (midostaurin - unii:id912s5von) - midostaurin 25 mg - rydapt is indicated in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, as detected by an fda approved test [see dosage and administration (2.1), clinical studies (14.1)]. limitations of use rydapt is not indicated as a single-agent induction therapy for the treatment of patients with aml. rydapt is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl). rydapt is contraindicated in patients with hypersensitivity to midostaurin or to any of the excipients [see description (11)]. hypersensitivity reactions have included anaphylactic shock, dyspnea, flushing, chest pain, and angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment) [see adverse reactions (6.1)]. pregnanc